
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>L49</td><td>1</td><td>Cilostazol</td><td>Bisoprolol</td><td>Bisoprolol may decrease the excretion rate of Cilostazol which could result in a
higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Cilostazol</td><td>Eplerenone</td><td>Eplerenone may increase the excretion rate of Cilostazol which could result in a
lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>L49</td><td>1</td><td>Cilostazol</td><td>Furosemide</td><td>Furosemide may decrease the excretion rate of Cilostazol which could result in a
higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Cilostazol</td><td>Nifedipine</td><td>The metabolism of Cilostazol can be decreased when combined with Nifedipine.</td></tr><tr><td>L49</td><td>1</td><td>Cilostazol</td><td>Pantoprazole</td><td>The serum concentration of Cilostazol can be increased when it is combined with
Pantoprazole.</td></tr><tr><td>L49</td><td>1</td><td>Cilostazol</td><td>Pregabalin</td><td>The risk or severity of QTc prolongation can be increased when Pregabalin is
combined with Cilostazol.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Bisoprolol</td><td>The serum concentration of Dabigatran etexilate can be increased when it is
combined with Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Cilostazol</td><td>Cilostazol may increase the anticoagulant activities of Dabigatran etexilate.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Eplerenone</td><td>Eplerenone may increase the excretion rate of Dabigatran etexilate which could
result in a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Furosemide</td><td>Furosemide may decrease the excretion rate of Dabigatran etexilate which could
result in a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Nifedipine</td><td>Nifedipine may decrease the excretion rate of Dabigatran etexilate which could
result in a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Pantoprazole</td><td>Pantoprazole can cause a decrease in the absorption of Dabigatran etexilate
resulting in a reduced serum concentration and potentially a decrease in
efficacy.</td></tr><tr><td>L49</td><td>1</td><td>Dabigatran etexilate</td><td>Pregabalin</td><td>Pregabalin may decrease the excretion rate of Dabigatran etexilate which could
result in a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Empagliflozin</td><td>Bisoprolol</td><td>The therapeutic efficacy of Empagliflozin can be increased when used in
combination with Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Empagliflozin</td><td>Eplerenone</td><td>Empagliflozin may increase the diuretic activities of Eplerenone.</td></tr><tr><td>L49</td><td>1</td><td>Eplerenone</td><td>Bisoprolol</td><td>Bisoprolol may increase the hypotensive activities of Eplerenone.</td></tr><tr><td>L49</td><td>1</td><td>Furosemide</td><td>Bisoprolol</td><td>Bisoprolol may increase the hypotensive activities of Furosemide.</td></tr><tr><td>L49</td><td>1</td><td>Furosemide</td><td>Empagliflozin</td><td>Empagliflozin may increase the diuretic activities of Furosemide.</td></tr><tr><td>L49</td><td>1</td><td>Furosemide</td><td>Eplerenone</td><td>Furosemide may increase the hypotensive activities of Eplerenone.</td></tr><tr><td>L49</td><td>1</td><td>Nifedipine</td><td>Bisoprolol</td><td>The risk or severity of congestive heart failure and hypotension can be
increased when Nifedipine is combined with Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Nifedipine</td><td>Empagliflozin</td><td>The risk or severity of hypoglycemia can be increased when Nifedipine is
combined with Empagliflozin.</td></tr><tr><td>L49</td><td>1</td><td>Nifedipine</td><td>Eplerenone</td><td>The risk or severity of adverse effects can be increased when Eplerenone is
combined with Nifedipine.</td></tr><tr><td>L49</td><td>1</td><td>Nifedipine</td><td>Ezetimibe</td><td>Ezetimibe may decrease the excretion rate of Nifedipine which could result in a
higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Nifedipine</td><td>Furosemide</td><td>The risk or severity of adverse effects can be increased when Furosemide is
combined with Nifedipine.</td></tr><tr><td>L49</td><td>1</td><td>Nifedipine</td><td>Pregabalin</td><td>The risk or severity of QTc prolongation can be increased when Pregabalin is
combined with Nifedipine.</td></tr><tr><td>L49</td><td>1</td><td>Pantoprazole</td><td>Bisoprolol</td><td>Pantoprazole may decrease the excretion rate of Bisoprolol which could result in
a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Pantoprazole</td><td>Eplerenone</td><td>Eplerenone may increase the excretion rate of Pantoprazole which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>L49</td><td>1</td><td>Pantoprazole</td><td>Ezetimibe</td><td>Pantoprazole may decrease the excretion rate of Ezetimibe which could result in
a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Pantoprazole</td><td>Furosemide</td><td>Furosemide may decrease the excretion rate of Pantoprazole which could result in
a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Pantoprazole</td><td>Nifedipine</td><td>Pantoprazole may decrease the excretion rate of Nifedipine which could result in
a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Pantoprazole</td><td>Pregabalin</td><td>Pantoprazole may decrease the excretion rate of Pregabalin which could result in
a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Bisoprolol</td><td>Pentoxifylline may increase the hypotensive activities of Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Cilostazol</td><td>Pentoxifylline may increase the antiplatelet activities of Cilostazol.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Dabigatran etexilate</td><td>The therapeutic efficacy of Dabigatran etexilate can be increased when used in
combination with Pentoxifylline.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Eplerenone</td><td>Pentoxifylline may increase the hypotensive activities of Eplerenone.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Furosemide</td><td>Pentoxifylline may increase the hypotensive activities of Furosemide.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Nifedipine</td><td>The metabolism of Nifedipine can be decreased when combined with Pentoxifylline.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Pentoxifylline which could
result in a higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Pentoxifylline</td><td>Pregabalin</td><td>Pregabalin may increase the excretion rate of Pentoxifylline which could result
in a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>L49</td><td>1</td><td>Pregabalin</td><td>Bisoprolol</td><td>Pregabalin may increase the bradycardic activities of Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Pregabalin</td><td>Empagliflozin</td><td>The risk or severity of hypoglycemia can be increased when Pregabalin is
combined with Empagliflozin.</td></tr><tr><td>L49</td><td>1</td><td>Pregabalin</td><td>Eplerenone</td><td>Eplerenone may increase the excretion rate of Pregabalin which could result in a
lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>L49</td><td>1</td><td>Pregabalin</td><td>Furosemide</td><td>Furosemide may decrease the excretion rate of Pregabalin which could result in a
higher serum level.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Bisoprolol</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Cilostazol</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Cilostazol.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Dabigatran etexilate</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Dabigatran etexilate.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Furosemide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Furosemide.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Nifedipine</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Nifedipine.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Pantoprazole</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Pantoprazole.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Pentoxifylline</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Pentoxifylline.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Pregabalin</td><td>The serum concentration of Tenofovir alafenamide can be decreased when it is
combined with Pregabalin.</td></tr><tr><td>L49</td><td>1</td><td>Tenofovir alafenamide</td><td>Valsartan</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Valsartan.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Bisoprolol</td><td>Valsartan may increase the hypotensive activities of Bisoprolol.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Empagliflozin</td><td>The risk or severity of adverse effects can be increased when Valsartan is
combined with Empagliflozin.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Eplerenone</td><td>The risk or severity of hyperkalemia can be increased when Eplerenone is
combined with Valsartan.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Ezetimibe</td><td>The excretion of Ezetimibe can be decreased when combined with Valsartan.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Furosemide</td><td>The risk or severity of renal failure and hypotension can be increased when
Furosemide is combined with Valsartan.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Nifedipine</td><td>The risk or severity of adverse effects can be increased when Valsartan is
combined with Nifedipine.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Pantoprazole</td><td>The excretion of Valsartan can be decreased when combined with Pantoprazole.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Pentoxifylline</td><td>Pentoxifylline may increase the hypotensive activities of Valsartan.</td></tr><tr><td>L49</td><td>1</td><td>Valsartan</td><td>Pregabalin</td><td>The risk or severity of angioedema can be increased when Valsartan is combined
with Pregabalin.</td></tr></tbody></table></div>
